Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …

Background Afamitresgene autoleucel (afami-cel) showed acceptable safety and promising
efficacy in a phase 1 trial (NCT03132922). The aim of this study was to further evaluate the …

The available treatments for relapsed or refractory (R/R) diffuse large B-cell lymphoma
(DLBCL) have experienced a dramatic change since 2017. Incremental advances in basic …

Abstract The US Food and Drug Administration (FDA) has reported cases of T-cell
malignancies, including CAR-positive lymphomas, in patients receiving B cell maturation …

Real-world evidence suggests a trend toward inferior survival of patients receiving CD19
chimeric antigen receptor (CAR) T-cell therapy in Europe (EU) and with tisagenlecleucel …

Autologous chimeric antigen receptor-modified T-cell (CAR T) products have demonstrated
un-precedent efficacy in treating many relapsed/refractory B-cell and plasma cell …

The introduction of chimeric antigen receptor (CAR) T-cell therapy has led to a fundamental
shift in the management of relapsed and refractory large B-cell lymphoma. However, our …

Chimeric antigen receptor T‐cell (CAR T) therapy has shown promising efficacy in relapsed
and refractory diffuse large B cell lymphoma (DLBCL). While most patients undergo CAR T …

Patients with large B-cell lymphoma (LBCL) that fail to achieve a complete response (CR) or
who relapse early after anthracycline-containing immunochemotherapy (IC) have a poor …

Background The first-in-class approved BCMA CAR-T therapy was idecabtagene vicleucel
(ide-cel), approved in March 2021, for RRMM patients who progressed after 4 or more lines …